Betamethasone Dipropionate/Clotrimazole (Lotriderm)
Is It Right for You?
A complete guide to Betamethasone Dipropionate/Clotrimazole (Lotriderm) — what it treats, how it works, dosages, side effects, and when a clinician may prescribe it following an online consultation.
What Is Lotriderm?
Lotriderm is a combination topical cream containing betamethasone dipropionate 0.05% — a potent corticosteroid — and clotrimazole 1% — a broad-spectrum imidazole antifungal. This dual formulation is specifically designed to treat skin conditions where both fungal infection and associated inflammation are present simultaneously, delivering antifungal and anti-inflammatory activity in a single application.
Betamethasone dipropionate is classified as a potent topical corticosteroid (Group III in the UK classification), providing rapid and effective suppression of the inflammatory response that accompanies fungal skin infections. Clotrimazole provides reliable activity against dermatophytes, Candida species, and Malassezia — the most common pathogens in inflammatory tinea and cutaneous candidiasis.
Lotriderm is a prescription-only medication in the UK, due to the risk of local and systemic side effects associated with potent topical corticosteroids.
What Conditions Is Lotriderm Used For?
Lotriderm is indicated for:
Fungal infection of the feet with prominent redness, scaling, and itch where inflammation warrants corticosteroid co-treatment
fungal infection of the groin and upper inner thighs
fungal infection of the body surface
Lotriderm contains a potent steroid and is not appropriate for uncomplicated fungal infections where inflammation is absent or mild. Clotrimazole alone (Canesten) is the first-line treatment for uncomplicated tinea and cutaneous candidiasis. Lotriderm is reserved for cases where the inflammatory component is significant enough to justify corticosteroid co-therapy. It should not be used for longer than 2–4 weeks on most sites.
How Does Lotriderm Work?
Lotriderm's efficacy comes from the combined and synergistic action of its two active components:
Betamethasone dipropionate is a halogenated glucocorticoid with potent topical anti-inflammatory and antipruritic activity. Following skin penetration, it binds intracellular glucocorticoid receptors in keratinocytes and dermal immune cells, suppressing the production of pro-inflammatory cytokines, reducing vasodilation and vascular permeability, and inhibiting the migration of inflammatory cells into the skin. This rapidly reduces the erythema, oedema, scaling, and itch that characterise inflamed tinea and candidal infections.
Clotrimazole is a synthetic imidazole antifungal that acts primarily by inhibiting ergosterol synthesis in the fungal cell membrane. It inhibits the cytochrome P450 enzyme lanosterol 14-α-demethylase, blocking the conversion of lanosterol to ergosterol — the essential sterol component of fungal cell membranes. This results in membrane disruption, leakage of cellular contents, and fungal cell death. Clotrimazole is active against dermatophytes (Trichophyton, Microsporum, Epidermophyton), Candida albicans and other Candida species, and Malassezia furfur.
The combination ensures that both the cause (fungal infection) and the inflammatory response (which drives patient symptoms) are treated concurrently.
Dosages & Administration
The correct dose depends on the type and severity of infection, age, weight, and kidney function. Always follow your clinician's instructions. The table below is for general reference only.
Administration Tips
Apply a thin layer only. A thin smear is sufficient; excessive application increases systemic absorption of betamethasone and risk of local side effects without improving efficacy.
Avoid the face, axillae, and groin unless specifically directed. These sites have thin skin and enhanced corticosteroid absorption; use only if specifically prescribed for these areas and do not exceed 1 week on the face.
Do not use under occlusion (e.g., under nappies, clingfilm, or tight dressings) unless specifically directed — occlusion significantly increases systemic corticosteroid absorption.
Do not use in or around the eyes corticosteroids applied periocularly can cause glaucoma and cataracts.
Complete the prescribed course. Continue for the full duration even if symptoms improve quickly, to ensure fungal eradication.
Wash hands before and after application (unless the hands are the area being treated).
Side Effects of Lotriderm
Most side effects are mild and resolve on their own. Serious side effects are rare but require immediate medical attention.
- Local burning, stinging, or itching on initial application
- Skin dryness or mild irritation at the application site
- Erythema (skin redness) on application — often transient
- Skin atrophy — thinning, fragility, striae (stretch marks), and telangiectasia with prolonged or excessive use of potent topical corticosteroids; irreversible once established
- HPA axis suppression — risk with extensive, prolonged, or occluded application; more significant in children and on thin skin sites
- Glaucoma and cataracts — periocular application or heavy use on the face can raise intraocular pressure
Betamethasone dipropionate is a potent topical corticosteroid. Prolonged use beyond recommended durations, application to thin skin sites, and use under occlusion all significantly increase the risk of irreversible skin atrophy. Lotriderm should not be used continuously for more than 4 weeks at any skin site.
Drug Interactions
Lotriderm may interact with other medications, including systemic corticosteroids and other topical antifungals. Always inform your clinician about all medications you are taking.
concurrent systemic corticosteroid therapy increases total corticosteroid load; risk of HPA axis suppression is amplified with extensive topical betamethasone use; use the minimum effective amount.
no clinically significant interactions; avoid combining with other potent topical steroids.
Topical calcineurin inhibitors should not be used at the same site concurrently; no systemic interaction expected.
Important Warnings
Betamethasone dipropionate should not be used on facial skin for more than 5–7 days without specialist review. The face is highly sensitive to corticosteroid-induced atrophy, telangiectasia, perioral dermatitis, and rosacea exacerbation.
Lotriderm should not be used as first-line therapy for uncomplicated tinea or candidiasis without significant inflammation. Antifungal monotherapy (e.g., clotrimazole 1% cream) is the appropriate first-line agent in these cases.
Children are more susceptible to topical corticosteroid-induced adrenal suppression due to their higher body surface area-to-volume ratio. Lotriderm should be used in children with caution, for the shortest possible duration, and in the smallest effective quantity.
Extensive or prolonged use of potent topical steroids in pregnancy is not recommended due to potential fetal effects. Brief, localised use is generally considered low risk. Seek clinician guidance.
Speak to a Clinician About Treatment
Getting advice no longer means sitting in a waiting room. Through The GP Service, you can consult with a licensed clinician in minutes — from home, on your lunch break, or wherever works for you. If treatment is clinically appropriate, your clinician can issue a prescription during the consultation. A consultation does not guarantee a prescription.
The treatment you need, when you need it.
Lotriderm FAQs
Canesten (clotrimazole alone) is the standard first-line treatment for uncomplicated fungal skin infections. Lotriderm is prescribed when there is significant inflammation — redness, swelling, and itch — alongside the fungal infection, where the added betamethasone will speed up symptomatic relief while the clotrimazole eradicates the fungus.
Typically 2–4 weeks, depending on the site and severity. Do not use for longer than prescribed without review. The steroid component carries a risk of skin thinning with prolonged use.
Only if specifically directed by your clinician. Facial skin is particularly susceptible to corticosteroid side effects including atrophy, telangiectasia, and rosacea. Use on the face is generally limited to 5–7 days maximum.
If your skin condition is worsening rather than improving after 5–7 days of treatment, contact your clinician. Worsening may indicate an incorrect diagnosis, a bacterial superinfection, or a contact allergy to one of the cream's components.
Yes — betamethasone dipropionate is a potent corticosteroid, and prolonged or excessive use can cause irreversible skin atrophy (thinning), stretch marks, and visible blood vessels. Using the minimum effective amount for the shortest possible time, and avoiding sensitive skin areas unless directed, minimises this risk.